Tel: 01892 526726     Email:     Twitter

Broad and learned
clinical background

Gut Reaction #14: Risankizumab – Targeting interleukin 23 for Crohn’s disease

Gut Reaction #14: Risankizumab - Targeting interleukin 23 for Crohn’s disease The Lancet recently published results from a study which assessed the efficacy and safety of risankizumab, a monoclonal antibody that targets interleukin-23 only (ustekinumab targets interleukin-21 and 23), in ...

Read more

Twitter has returned errors:

  • “Rate limit exceeded [error code: 88]”

More information on errors that have codes here.